Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Secukinumab in Psoriasis: NCT07254325 Clinical Landscape Report 2026
15 October 2026
NCT07254325 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07255872 Clinical Landscape Report 2026
15 October 2026
NCT07255872 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rebecsinib in Acute Myeloid Leukemia: NCT07250646 Clinical Landscape Report 2026
15 October 2026
NCT07250646 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Metastatic Carcinoma to the Uterine Cervix: NCT07256236 Clinical Landscape Report 2026
15 October 2026
NCT07256236 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant(Emmanuel College, University of Queensland) in Human Papillomavirus Infection: NCT07256912 Clinical Landscape Report 2026
15 October 2026
NCT07256912 clinical landscape for Human Papillomavirus Infection: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donor-derived Natural Killer Cell(Federal Research Institute of Pediatric Hematology) in Acute Myeloid Leukemia: NCT07256210 Clinical Landscape Report 2026
15 October 2026
NCT07256210 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BL-M24D1 in Hematologic Neoplasms: NCT07255898 Clinical Landscape Report 2026
15 October 2026
NCT07255898 clinical landscape for Hematologic Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Risankizumab Biosimilar (Chong Kun Dang) in Psoriasis: NCT07258745 Clinical Landscape Report 2026
15 October 2026
NCT07258745 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gilteritinib Fumarate in Acute Myeloid Leukemia with FLT3/ITD Mutation: NCT07259707 Clinical Landscape Report 2026
15 October 2026
NCT07259707 clinical landscape for Acute Myeloid Leukemia with FLT3/ITD Mutation: endpoints, sponsor, phase, geography, readouts, asset context and developme…
9 min read
Lithium succinate in Alzheimer Disease: ISRCTN18150075 Clinical Landscape Report 2026
15 October 2026
ISRCTN18150075 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ramantamig in Multiple Myeloma: NCT07258511 Clinical Landscape Report 2026
15 October 2026
NCT07258511 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Recurrent ovarian cancer: NCT07261683 Clinical Landscape Report 2026
15 October 2026
NCT07261683 clinical landscape for Recurrent ovarian cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.